BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Significant Increase in Short Interest

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 21,810,000 shares, a growth of 22.0% from the June 30th total of 17,880,000 shares. Based on an average daily volume of 3,620,000 shares, the days-to-cover ratio is currently 6.0 days.

Insider Buying and Selling at BioCryst Pharmaceuticals

In related news, Director Machelle Sanders sold 4,689 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $6.00, for a total transaction of $28,134.00. Following the completion of the transaction, the director now owns 27,742 shares in the company, valued at $166,452. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other BioCryst Pharmaceuticals news, CFO Anthony Doyle bought 36,300 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was bought at an average price of $5.57 per share, for a total transaction of $202,191.00. Following the completion of the acquisition, the chief financial officer now directly owns 266,744 shares in the company, valued at $1,485,764.08. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Machelle Sanders sold 4,689 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $6.00, for a total value of $28,134.00. Following the transaction, the director now owns 27,742 shares of the company’s stock, valued at approximately $166,452. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 103,601 shares of company stock worth $596,338. 4.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. Leisure Capital Management bought a new position in shares of BioCryst Pharmaceuticals in the second quarter worth approximately $173,000. Bank of New York Mellon Corp lifted its stake in shares of BioCryst Pharmaceuticals by 12.5% in the second quarter. Bank of New York Mellon Corp now owns 775,957 shares of the biotechnology company’s stock worth $4,795,000 after buying an additional 86,249 shares in the last quarter. Diversified Trust Co lifted its stake in shares of BioCryst Pharmaceuticals by 18.0% in the second quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company’s stock worth $153,000 after buying an additional 3,774 shares in the last quarter. CWM LLC lifted its stake in shares of BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after buying an additional 3,772 shares in the last quarter. Finally, Tidal Investments LLC bought a new position in shares of BioCryst Pharmaceuticals in the first quarter worth approximately $282,000. Institutional investors own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. Finally, JMP Securities raised their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a research report on Tuesday, May 7th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $14.67.

BioCryst Pharmaceuticals Trading Up 4.0 %

NASDAQ:BCRX traded up $0.30 during mid-day trading on Friday, hitting $7.85. 2,359,725 shares of the company’s stock were exchanged, compared to its average volume of 2,806,823. BioCryst Pharmaceuticals has a one year low of $4.03 and a one year high of $7.95. The business has a fifty day moving average price of $6.59 and a 200 day moving average price of $5.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. The business had revenue of $92.80 million for the quarter, compared to the consensus estimate of $85.62 million. During the same period in the previous year, the firm earned ($0.28) EPS. The company’s revenue was up 34.9% on a year-over-year basis. As a group, analysts forecast that BioCryst Pharmaceuticals will post -0.65 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.